

Prof. Yvette van Kooyk Joins United Immunity's Scientific Advisory Board

Tokyo, Japan, September 2, 2024 - United Immunity Co., Ltd., an innovative biotech company developing a Myeloid Targeting Platform™, announced today that Prof. Yvette van Kooyk has joined the company's scientific advisory board (SAB).

Prof. van Kooyk is head of the department Molecular Cell Biology and Immunology at Amsterdam University Medical Center. She is an expert and key opinion leader regarding the role of glycosylation on innate and adaptive immune responses in cancer, allergy and autoimmunity. Her research has also characterized the function of the C-type lectin receptor DC-SIGN (CD209) in macrophages and dendritic cells. She was awarded the SPINOZA prize and van Loghem award for lifetime achievements in field of Glyco-Immunology and is a member of the Royal Netherlands Academy of Arts and Sciences.

"We are very pleased to welcome Prof. van Kooyk to our scientific advisory board," said Dr. Naozumi Harada, Founder and Chairman of United Immunity. "Her pioneering work with DC-SIGN will allow us to better understand how our pullulan nanoparticles and pullulan lipid nanoparticles interacts with the receptor to deliver therapeutic payloads selectively to myeloid cells."

Prof. van Kooyk said "I am delighted to be joining United's SAB and look forward in closely working with the leadership team to advance development of their myeloid targeting platform in their pursuit of creating new treatment modalities for patients with cancer and infectious diseases."

United's scientific advisory board also includes Prof. Kazunari Akiyoshi from the Department of Immunology, Kyoto University who supports the company with nanotechnology engineering and Dr. Shigehisa Kitano from Japanese Foundation for Cancer Research who advises United in the field of clinical immuno-oncology.

About United Immunity, Co., Ltd.

**Unite the power of immunity and nanoparticle,
change the future of patients**

United Immunity is an innovative biotech company developing a Myeloid Targeting Platform™ comprising of pullulan-based nanoparticles (PNP) and lipid nanoparticles (Pullulan-LNP) to

target therapeutic payloads (small molecules, nucleic acids, peptides, proteins, etc.) to macrophages, dendritic cells and other myeloid cells for the treatment of cancer, fibrosis, infectious, metabolic, autoimmune, and inflammatory diseases. The company's lead program, UI-102, uses pullulan nanoparticles to deliver a TLR agonist to tumor-associated macrophages and change refractory cold tumors into hot tumors. United's platform is also being applied to T-cell booster vaccines and in-vivo CAR-macrophages.

For more information, please visit www.unitedimmunity.co.jp/eng/
www.linkedin.com/company/unitedimmunitycoltd

Contact

Masato Kishida, President

e-mail: info@unitedimmunity.co.jp

Phone: 03-6265-1670